Off-Label Rituximab Matches Ocrelizumab in MS Trial

Off-label rituximab demonstrated noninferiority to ocrelizumab (Ocrevus) in patients with newly diagnosed relapsing multiple sclerosis (MS) and recent disease activity, according to the phase III OVERLORD-MS trial. The study, which followed participants for 2 years, indicated comparable efficacy between the two treatments.

The OVERLORD-MS trial measured the estimated probability of disease activity at the 2-year mark. While specific percentages were not detailed in the initial report, the trial's design aimed to establish that rituximab's performance was not worse than ocrelizumab by a predefined margin. This finding is significant as rituximab, a B-cell depleting antibody, is approved for other autoimmune conditions but is used off-label for MS.

Ocrelizumab is a B-cell depleting therapy specifically approved for relapsing forms of MS and primary progressive MS. The trial's results suggest that clinicians may have an additional therapeutic option for managing relapsing MS, potentially offering flexibility in treatment selection. The study's findings will be presented in full at an upcoming medical conference, where detailed data on efficacy and safety endpoints are expected to be revealed.

This trial addresses a critical need for comparative effectiveness data in MS treatment, particularly concerning off-label use of established therapies. The implications for patient care and treatment guidelines could be substantial, pending further analysis and regulatory review. The OVERLORD-MS trial was funded by the National Institute for Health Research (NIHR) and conducted by researchers at University College London Hospitals and other UK centers.